These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2979114)

  • 1. Cardiopulmonary bypass interference with dantrolene prophylaxis of malignant hyperthermia.
    Larach DR; High KM; Larach MG; Hensley FA; Martin DE; Williams DR
    J Cardiothorac Anesth; 1987 Oct; 1(5):448-53. PubMed ID: 2979114
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of dantrolene in an adult patient undergoing cardiopulmonary bypass.
    Comunale ME; DiNardo JA; Schwartz MJ
    J Cardiothorac Vasc Anesth; 1991 Apr; 5(2):153-5. PubMed ID: 1863728
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of malignant hyperthermia obscured by cardiopulmonary bypass.
    MacGillivray RG; Jann H; Vanker E; Gemmell L; Mahomedy AE
    Can Anaesth Soc J; 1986 Jul; 33(4):509-14. PubMed ID: 3742327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prophylaxis of malignant hyperthermia by oral dantrolene sodium in swine.
    Harrison GG
    Br J Anaesth; 1977 Apr; 49(4):315-7. PubMed ID: 889645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant hyperthermia susceptibility--successful management with a "stressfree" technique.
    Jantzen JP; Erdmann K; Kleemann PP
    Acta Anaesthesiol Belg; 1987; 38(1):107-13. PubMed ID: 3591264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful use of dantrolene sodium in human malignant hyperthermia syndrome: a case report.
    Friesen CM; Brodsky JB; Dillingham MF
    Can Anaesth Soc J; 1979 Jul; 26(4):319-21. PubMed ID: 509349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous dantrolene in children.
    Lerman J; McLeod ME; Strong HA
    Anesthesiology; 1989 Apr; 70(4):625-9. PubMed ID: 2929999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anesthesia for elective surgery in patients susceptible to malignant hyperthermia.
    Relton JE
    Int Anesthesiol Clin; 1979; 17(4):141-51. PubMed ID: 521179
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prophylaxis with dantrolene sodium in 2 patients with susceptibility to malignant hyperthermia].
    Navas E; Sánchez-Peña J; Gutiérrez-Crespo A
    Rev Esp Anestesiol Reanim; 1992; 39(5):309-11. PubMed ID: 1410753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General anesthesia in a malignant hyperthermia susceptible patient.
    Jones JE; Dierdorf SF; Clapp DW
    J Oral Med; 1987; 42(1):22-4, 66. PubMed ID: 2950215
    [No Abstract]   [Full Text] [Related]  

  • 11. [A case of malignant hyperthermia; successful treatment with intravenous dantrolene sodium].
    Noda B; Higa K; Naitoh H; Dan K
    Masui; 1985 Jun; 34(6):822-7. PubMed ID: 4032707
    [No Abstract]   [Full Text] [Related]  

  • 12. Rewarming following hypothermic cardiopulmonary bypass in the malignant hyperthermia-susceptible patient: implications for diagnosis and perioperative management.
    Allen GC; Cattran CB
    Can J Anaesth; 1989 Jan; 36(1):81-5. PubMed ID: 2914339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of dantrolene following oral administration in malignant hyperthermia-susceptible patients.
    Allen GC; Cattran CB; Peterson RG; Lalande M
    Anesthesiology; 1988 Dec; 69(6):900-4. PubMed ID: 3057938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant hyperthermia and charcoal absorbent: too hot to handle.
    Block FE
    Anesth Analg; 2011 Jun; 112(6):1270-1. PubMed ID: 21613194
    [No Abstract]   [Full Text] [Related]  

  • 15. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.
    Ward A; Chaffman MO; Sorkin EM
    Drugs; 1986 Aug; 32(2):130-68. PubMed ID: 3527659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaesthesia in malignant hyperthermia-susceptible patients without dantrolene prophylaxis: a report of 30 cases.
    Hackl W; Mauritz W; Winkler M; Sporn P; Steinbereithner K
    Acta Anaesthesiol Scand; 1990 Oct; 34(7):534-7. PubMed ID: 2244439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is the prevention of peranesthetic malignant hyperthermia with dantrolene justified?].
    Welfringer P; Cornet C
    Ann Fr Anesth Reanim; 1988; 7(5):437-8. PubMed ID: 3207236
    [No Abstract]   [Full Text] [Related]  

  • 18. Presumed Malignant Hyperthermia Treated During Cardiopulmonary Bypass in a Pediatric Patient Undergoing Aortic Valve Replacement: A Case Report.
    Kuntz MT; Saab AD
    A A Pract; 2019 Apr; 12(7):246-248. PubMed ID: 30299295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed Development of Malignant Hyperthermia Following Cardiopulmonary Bypass.
    Sams SH; Revilla S; Stahl DL
    Semin Cardiothorac Vasc Anesth; 2018 Mar; 22(1):95-99. PubMed ID: 28922985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective use of dantrolene in a patient susceptible to malignant hyperthermia.
    Gallagher DM; Hyer RL
    J Oral Surg; 1980 Jun; 38(6):438-40. PubMed ID: 6929328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.